- Home
- IMNM vs CAPL Comparison
IMNM vs CAPL Comparison
Compare IMNM & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- CAPL
- Stock Information
- Founded
- IMNM 2006
- CAPL 1992
- Country
- IMNM United States
- CAPL United States
- Employees
- IMNM N/A
- CAPL N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- CAPL Oil Refining/Marketing
- Sector
- IMNM Health Care
- CAPL Energy
- Exchange
- IMNM Nasdaq
- CAPL Nasdaq
- Market Cap
- IMNM 747.7M
- CAPL 804.3M
- IPO Year
- IMNM 2020
- CAPL 2012
- Fundamental
- Price
- IMNM $12.09
- CAPL $21.49
- Analyst Decision
- IMNM Strong Buy
- CAPL
- Analyst Count
- IMNM 4
- CAPL 0
- Target Price
- IMNM $28.75
- CAPL N/A
- AVG Volume (30 Days)
- IMNM 761.5K
- CAPL 22.8K
- Earning Date
- IMNM 11-07-2024
- CAPL 11-05-2024
- Dividend Yield
- IMNM N/A
- CAPL 9.77%
- EPS Growth
- IMNM N/A
- CAPL N/A
- EPS
- IMNM N/A
- CAPL 0.56
- Revenue
- IMNM $10,784,000.00
- CAPL $3,996,818,000.00
- Revenue This Year
- IMNM N/A
- CAPL $14.36
- Revenue Next Year
- IMNM N/A
- CAPL N/A
- P/E Ratio
- IMNM N/A
- CAPL $38.30
- Revenue Growth
- IMNM 62.73
- CAPL N/A
- 52 Week Low
- IMNM $6.93
- CAPL $18.43
- 52 Week High
- IMNM $30.96
- CAPL $24.19
- Technical
- Relative Strength Index (RSI)
- IMNM 36.69
- CAPL 56.40
- Support Level
- IMNM $11.81
- CAPL $21.54
- Resistance Level
- IMNM $12.44
- CAPL $21.97
- Average True Range (ATR)
- IMNM 0.68
- CAPL 0.30
- MACD
- IMNM -0.11
- CAPL 0.00
- Stochastic Oscillator
- IMNM 11.61
- CAPL 63.31
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver, includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K and through company operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites and the retail sale of motor fuel at retail sites operated by commission agents.